Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis
Conditions
Interventions
Ravulizumab
Placebo
Locations
111
United States
Research Site
Phoenix, Arizona, United States
Research Site
Irvine, California, United States
Research Site
Santa Monica, California, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Tampa, Florida, United States
Research Site
Atlanta, Georgia, United States
Start Date
November 19, 2021
Primary Completion Date
October 26, 2023
Completion Date
May 8, 2024
Last Updated
July 9, 2025
NCT07089121
NCT04402086
NCT07160205
NCT07374107
NCT06347718
NCT06371417
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions